Truist initiated coverage of MannKind (MNKD) with a Buy rating and $9 price target MannKind continues to execute with their technology, with both Afrezza and Tyvaso DPI, and the recent acquisition of scPharmaceuticals adds another topline driver, Furoscix, for fluid overload, the analyst tells investors in a research note. MannKind’s orphan lung pipeline continues to advance for longer-term diversification and growth for the company, Truist says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind price target lowered to $10 from $15 at Oppenheimer
- MannKind’s Strategic Advancements and Product Potential Justify Buy Rating Despite MNKD-101 Discontinuation
- Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
- H.C. Wainwright remains bullish on MannKind despite disappointing MNKD-101 news
- MannKind’s Resilience and Growth Potential: A Buy Rating Amid Setbacks and Opportunities